Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of the drugs
ZarnestraTM (R115777) and Gleevec (imatinib mesylate) that can be given in combination for
the treatment of chronic myelogenous leukemia (CML) in chronic phase. The effect of this
combination on the leukemia will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.